Strategically, looks like a good buy, but BioSource, if I am reading the financials right, is barely profitable. This makes the price a bit off, but they obviously weren't bought for the short term shot in the arm of cash.
$680,000 in Q1 '05
losses overall for every previous year. I hope, and acutally find likely, that they were doing something to burn all that money. I am too lazy to read, but it looks like they wrote something off that made them not profitable last year. If they hadn't they would have squeezed out a profit. SG&A is really big.
In other news, this puts Invitrogen on the map as far as antibodies and ELISA's.